Masahiro Takeda, Seisuke Sakamoto, Hajime Uchida, Shohei Yoshimura, Seiichi Shimizu, Yoshihiro Hirata, Akinari Fukuda, Andrea Schlegel, Mureo Kasahara – 7 May 2019 – In liver transplantation (LT) for biliary atresia (BA) with situs inversus (SI), the surgical procedure is technically challenging due to multiple anatomical variations. We evaluated the surgical procedures and the outcomes in our patients and in the previously reported patients undergoing LT for BA with SI. Between November 2005 and October 2018, 235 children underwent LT with an overall 10‐year graft survival of 94.7%.

Zhong Xu, Meng Xu, Pin Liu, Shu Zhang, Runze Shang, Yu Qiao, Li Che, Silvia Ribback, Antonio Cigliano, Katja Evert, Rosa M. Pascale, Frank Dombrowski, Matthias Evert, Xi Chen, Diego F. Calvisi, Xin Chen – 7 May 2019 – Hepatocellular carcinoma (HCC) is a deadly form of liver cancer with limited treatment options. The c‐Myc transcription factor is a pivotal player in hepatocarcinogenesis, but the mechanisms underlying c‐Myc oncogenic activity in the liver remain poorly delineated.

Bharat Bhushan, Swati Banerjee, Shirish Paranjpe, Kelly Koral, Wendy M. Mars, John W. Stoops, Anne Orr, William C. Bowen, Joseph Locker, George K. Michalopoulos – 7 May 2019 – Epidermal growth factor receptor (EGFR) is a critical regulator of hepatocyte proliferation and liver regeneration. Our recent work indicated that EGFR can also regulate lipid metabolism during liver regeneration after partial hepatectomy. Based on these findings, we investigated the role of EGFR in a mouse model of nonalcoholic fatty liver disease (NAFLD) using a pharmacological inhibition strategy.

Jeanne‐Marie Giard, Jennifer L. Dodge, Norah A. Terrault – 7 May 2019 – Alcohol‐associated liver disease (ALD) is the most common indication for liver transplantation (LT) in the United States and Europe. A 6‐month alcohol abstinence period has been required by many transplant programs prior to listing, which may influence wait‐list (WL) outcomes. Therefore, we examined WL events in patients with ALD versus non‐ALD with a special interest in whether these outcomes differed by sex.

Puja S. Berry, Laura H. Rosenberger, Christopher A. Guidry, Avinash Agarwal, Shawn Pelletier, Robert G. Sawyer – 7 May 2019 – The appropriate duration of surgical antibiotic prophylaxis in orthotopic liver transplantation (OLT) in the presence of significant iatrogenic immunosuppression is unclear. We hypothesized that 72 hours of perioperative antibiotic prophylaxis would decrease rates of surgical site infection (SSI) in OLT patients when compared with intraoperative antibiotic prophylaxis alone.

Fei Ma, Yuekun Zhu, Xing Liu, Qingxin Zhou, Xuehui Hong, Chao Qu, Xing Feng, Yiyun Zhang, Qingbin Ding, Jiabao Zhao, Jingjing Hou, Mengya Zhong, Huiqin Zhuo, Lifeng Zhong, Zhijian Ye, Wen Xie, Yu Liu, Yubo Xiong, Hongwei Chen, Daxun Piao, Bei Sun, Zhi Gao, Qinghua Li, Zhen Zhang, Xingfeng Qiu, Zhiyong Zhang – 7 May 2019 – Cancer cells metabolize different energy sources to generate biomass rapidly. The purine biosynthetic pathway was recently identified as an important source of metabolic intermediates for these processes.

Florian Wrensch, Gaëtan Ligat, Laura Heydmann, Catherine Schuster, Mirjam B. Zeisel, Patrick Pessaux, François Habersetzer, Barnabas J. King, Alexander W. Tarr, Jonathan K. Ball, Michael Winkler, Stefan Pöhlmann, Zhen‐yong Keck, Steven K.H. Foung, Thomas F. Baumert – 7 May 2019 – Although adaptive immune responses against hepatitis C virus (HCV) infection have been studied in great detail, the role of innate immunity in protection against HCV infection and immune evasion is only partially understood.

Tanja Blumer, Isabel Fofana, Matthias S. Matter, Xueya Wang, Hesam Montazeri, Diego Calabrese, Mairene Coto‐Llerena, Tujana Boldanova, Sandro Nuciforo, Venkatesh Kancherla, Luigi Tornillo, Salvatore Piscuoglio, Stefan Wieland, Luigi M. Terracciano, Charlotte K.Y. Ng, Markus H. Heim – 6 May 2019 – Hepatocellular carcinoma (HCC) is the second leading cause of cancer‐related deaths worldwide. Treatment options for patients with advanced‐stage disease are limited. A major obstacle in drug development is the lack of an in vivo model that accurately reflects the broad spectrum of human HCC.

Adrian M. Di Bisceglie, Jeffrey Teckman – 6 May 2019

Sandeep Khurana, Harshit S. Khara – 2 May 2019